A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Trial details
- Registry ID
- NCT07795814
- Drugs studied
- EDG-15400 25 mg, EDG-15400 50 mg
TrialRedline tracks 6 clinical trials sponsored by Edgewise Therapeutics, Inc.: 6 Phase 2.
Company identity checked against sources
Names as written in the registry records.
NCT05291091 · Edgewise Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale. After: Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score.
Before: Estimated. After: Actual.
Before: Sep 2026. After: 7 Sep 2026.
Before: Active not recruiting. After: Completed.
NCT06347159 · Edgewise Therapeutics, Inc.
Before: 100 participants (planned). After: 79 participants (planned).
Before: Jun 2026. After: Dec 2027.
NCT06066580 · Edgewise Therapeutics, Inc.
Before: Aug 2029. After: Feb 2031.
NCT06347159 · Edgewise Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.
NCT05291091 · Edgewise Therapeutics, Inc.
Before: 175 participants (actual). After: 244 participants (actual).
NCT05291091 · Edgewise Therapeutics, Inc.
Before: Aug 2026. After: Sep 2026.
NCT06347159 · Edgewise Therapeutics, Inc.
Before: 75 participants (planned). After: 100 participants (planned).
Before: Mar 2026. After: Jun 2026.